US 11,926,668 B2
Anti-PD-1 antibodies for treatment of lung cancer
Petra Rietschel, Tarrytown, NY (US); and Israel Lowy, Dobbs Ferry, NY (US)
Assigned to Regeneron Pharmaceuticals Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Feb. 28, 2022, as Appl. No. 17/652,709.
Application 17/652,709 is a continuation of application No. 16/486,688, granted, now 11,292,842, previously published as PCT/US2018/018747, filed on Feb. 20, 2018.
Claims priority of provisional application 62/595,190, filed on Dec. 6, 2017.
Claims priority of provisional application 62/461,672, filed on Feb. 21, 2017.
Prior Publication US 2022/0281979 A1, Sep. 8, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 33/243 (2019.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/2818 (2013.01) [A61K 33/243 (2019.01); A61P 35/00 (2018.01); A61K 45/06 (2013.01)] 30 Claims
 
1. A method of treating non-small cell lung cancer (NSCLC) or increasing the survival of a patient with NSCLC, comprising:
(a) selecting a patient with NSCLC, wherein the patient has tested negative for epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) translocations, and ROS1 fusions; and
(b) administering to the patient one or more doses of platinum-based chemotherapy in combination with one or more doses of a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds specifically to PD-1, thereby treating NSCLC in the patient;
wherein the antibody or antigen-binding fragment thereof that binds specifically to PD-1 comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) of a heavy chain variable region (HCVR) and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) of a light chain variable region (LCVR), wherein HCDR1 comprises the amino acid sequence of SEQ ID NO: 3; HCDR2 comprises the amino acid sequence of SEQ ID NO: 4; HCDR3 comprises the amino acid sequence of SEQ ID NO: 5; LCDR1 comprises the amino acid sequence of SEQ ID NO: 6; LCDR2 comprises the amino acid sequence of SEQ ID NO: 7; and LCDR3 comprises the amino acid sequence of SEQ ID NO: 8.